Lenvatinib with or without Concurrent Drug-Eluting Beads Transarterial Chemoembolization in Patients with Unresectable, Advanced Hepatocellular Carcinoma: A Real-World, Multicenter, Retrospective Study

INTRODUCTION: Lenvatinib is the first-line treatment for advanced hepatocellular carcinoma (HCC). We aimed to compare the clinical outcomes of lenvatinib plus drug-eluting beads transarterial chemoembolization (DEB-TACE) versus lenvatinib alone in real-world practice. METHODS: This retrospective ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Dongdong, Bai, Wei, Wang, Enxin, Li, Jiaping, Chen, Xiaoming, Wang, Zhexuan, Huang, Mingsheng, Huang, Ming, Sun, Junhui, Yang, Weizhu, Lin, Zhengyu, Wu, Jianbing, Li, Zixiang, Yang, Shufa, Zhu, Xu, Chen, Zaizhong, Zhang, Yanfang, Fan, Wenzhe, Mai, Qicong, Ding, Rong, Nie, Chunhui, Feng, Long, Li, Xueda, Huang, Wukui, Sun, Jun, Wang, Qiuhe, Lv, Yong, Li, Xiaomei, Luo, Bohan, Wang, Zhengyu, Yuan, Jie, Guo, Wengang, Li, Kai, Li, Bing, Li, Ruijun, Yin, Zhanxin, Xia, Jielai, Han, Guohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294948/
https://www.ncbi.nlm.nih.gov/pubmed/35978600
http://dx.doi.org/10.1159/000523849

Ejemplares similares

Ejemplares similares